Introduction

Coronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential.

Areas covered

This review provides the current status of the development of various antibody-based immunotherapeutics such as convalescent plasma, mAbs, NAbs, and intravenous immunoglobulins against COVID-19. The review also highlights their advantages, disadvantages, and clinical utility for the treatment of COVID-19 patients.

Expert opinion

In a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19.

中文翻译：

---

基于抗体的免疫疗法和使用恢复性血浆对抗COVID-19：进展和前景。

介绍

2019年冠状病毒病（COVID-19）已传播到全球多个国家。当前，尚无可用于管理COVID-19的特定药物或疫苗。使用恢复性血浆，单克隆抗体（mAbs），中和抗体（NAbs）和静脉内免疫球蛋白的基于抗体的免疫治疗策略具有治疗潜力。

覆盖区域

这项审查提供了各种基于抗体的免疫疗法，例如恢复期血浆，mAb，NAb和针对COVID-19的静脉免疫球蛋白的开发现状。该评价还强调了它们在治疗COVID-19患者中的优缺点和临床应用。

专家意见

在大流行情况下（例如COVID-19），新药的开发应重点关注并加快已证明安全性和有效性的策略。基于抗体的免疫治疗方法，例如恢复期血浆，静脉内免疫球蛋白和mAb，已被证明具有安全性和有效性，并且已经使用了数十年。其中一些已经被用于治疗COVID-19患者，并被认为是有用的。然而，在这种COVID-19大流行期间，需要几小时的时间才能中和具有病毒中和能力的mAb，使其更具特异性和针对性。需要加速研究和投资，以使其针对COVID-19的预防和治疗目的进入临床。